Thomas Lehmann

431 total citations
9 papers, 211 citations indexed

About

Thomas Lehmann is a scholar working on Oncology, Orthopedics and Sports Medicine and Molecular Biology. According to data from OpenAlex, Thomas Lehmann has authored 9 papers receiving a total of 211 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 8 papers in Orthopedics and Sports Medicine and 4 papers in Molecular Biology. Recurrent topics in Thomas Lehmann's work include Bone health and treatments (8 papers), Bone health and osteoporosis research (7 papers) and Bone and Joint Diseases (4 papers). Thomas Lehmann is often cited by papers focused on Bone health and treatments (8 papers), Bone health and osteoporosis research (7 papers) and Bone and Joint Diseases (4 papers). Thomas Lehmann collaborates with scholars based in Switzerland and United States. Thomas Lehmann's co-authors include Judith Everts‐Graber, Stephan Reichenbach, Brigitta Gahl, HansJörg Häuselmann, Hans‐Rudolf Ziswiler, Benoît Schaller, Harald Bonél, Gernot Schmid, Christian Steiner and Albrecht W. Popp and has published in prestigious journals such as Journal of Bone and Mineral Research, Bone and Osteoporosis International.

In The Last Decade

Thomas Lehmann

8 papers receiving 206 citations

Peers

Thomas Lehmann

ONCOL

OSM

MB

SURGE

RHEUM

Carolyn Stewart United States

Christos Magopoulos Greece

Neveen A. T. Hamdy Netherlands

Lonneke W. Kessels Netherlands

D. Denarié France

Guochun Cao China

Giovanna Leonardi Italy

A. Arias Spain

Wahid Abu‐Amer United States

Ivan Krečak Croatia

Carolyn Stewart United States

Thomas Lehmann

120 ×0.7

ONCOL

12 ×0.1

OSM

48 ×0.5

MB

9 ×0.4

SURGE

32 ×1.7

RHEUM

Citations per year, relative to Thomas Lehmann Thomas Lehmann (= 1×) peers Carolyn Stewart

Countries citing papers authored by Thomas Lehmann

Since Specialization

Citations

This map shows the geographic impact of Thomas Lehmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Lehmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Lehmann more than expected).

Fields of papers citing papers by Thomas Lehmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Lehmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Lehmann. The network helps show where Thomas Lehmann may publish in the future.

Co-authorship network of co-authors of Thomas Lehmann

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Lehmann. A scholar is included among the top collaborators of Thomas Lehmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Lehmann. Thomas Lehmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Steiner, Christian, Hans‐Rudolf Ziswiler, Gernot Schmid, et al.. (2025). Long-term impact of teriparatide on bone mineral density, trabecular bone score, and fracture risk relative to total hip T-score: A two-decade, registry-based cohort study. Bone. 195. 117445–117445.

2.

Everts‐Graber, Judith, Serge Ferrari, Albrecht W. Popp, et al.. (2025). Early transition from short-term romosozumab to antiresorptive therapies: analysis of 26 cases. Archives of Osteoporosis. 20(1). 106–106. 2 indexed citations

3.

Everts‐Graber, Judith, Christian Steiner, Hans‐Rudolf Ziswiler, et al.. (2024). The effect of romosozumab on bone mineral density depending on prior treatment: a prospective, multicentre cohort study in Switzerland. Osteoporosis International. 35(9). 1605–1613. 5 indexed citations

4.

Everts‐Graber, Judith, Harald Bonél, Brigitta Gahl, et al.. (2023). Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study. Osteoporosis International. 34(11). 1961–1973. 8 indexed citations

5.

Everts‐Graber, Judith, Harald Bonél, Brigitta Gahl, et al.. (2022). Incidence of Atypical Femoral Fractures in Patients on Osteoporosis Therapy—A Registry‐Based Cohort Study. JBMR Plus. 6(10). e10681–e10681. 14 indexed citations

6.

Everts‐Graber, Judith, Stephan Reichenbach, Brigitta Gahl, et al.. (2022). Effects of zoledronate on bone mineral density and bone turnover after long-term denosumab therapy: Observations in a real-world setting. Bone. 163. 116498–116498. 18 indexed citations

7.

Everts‐Graber, Judith, Benoît Schaller, Brigitta Gahl, et al.. (2020). Risk of Osteonecrosis of the Jaw Under Denosumab Compared to Bisphosphonates in Patients With Osteoporosis. Journal of Bone and Mineral Research. 37(2). 340–348. 57 indexed citations

8.

Everts‐Graber, Judith, et al.. (2020). Risk factors for vertebral fractures and bone loss after denosumab discontinuation: A real-world observational study. Bone. 144. 115830–115830. 35 indexed citations

9.

Everts‐Graber, Judith, et al.. (2020). A Single Infusion of Zoledronate in Postmenopausal Women Following Denosumab Discontinuation Results in Partial Conservation of Bone Mass Gains. Journal of Bone and Mineral Research. 35(7). 1207–1215. 72 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact